Investigating the Resistance of Klebsiella Pneumoniae Clinical Isolates Producing Carbapenemase and ESBL Enzymes to Colistin and Fosfomycin Antibiotics

Authors

  • Ahmadi, Jalal Department of Microbiology, Faculty of Medicine, Yazd University of Medical Sciences, Yazd, Iran
  • Dadashi, Alireza Department of Infectious Diseases, Faculty of Medicine, Aja University of Medical Sciences, Tehran, Iran
Abstract:

 Introduction: A Klebsiella pneumoniae bacterium, which is the most important species of the Klebsiella genus, mainly causes hospital infections. Moreover, it has a high resistance to most of the available antibiotics, which has caused concern among doctors all over the world. Therefore, the amount of antibiotic resistance and the effect of these antibiotics on Klebsiella pneumoniae isolates producing carbapenemase and ESBL enzymes with multi-drug resistance are investigated in this research. Methods and Materials: Different strains of Klebsiella pneumoniae bacteria were identified and isolated from different clinical samples during 4 months (September 1400 to late December 1400) from hospitals and laboratories in Tehran. After determining the identity using biochemical tests, the isolates were investigated and re-identified by molecular method. Antibiotic resistance was determined by disk diffusion method. Then, the production of ESBL and carbapenemase were performed using the respective discs and checking the diameter of the inhibition zone. The ELISA test was repeated three times in order to investigate the creation of biofilm in strains with multiple resistances. Molecular testing was used again to identify fosA3, mcr1 and mcr2 genes. At the end, the results were evaluated using the software. Results: Out of 127 samples, 112 (88٪) isolates were of Klebsiella genus, and 80 (63٪) samples of Klebsiella pneumoniae were isolated using molecular tests.61 (76٪) samples had multidrug resistance. The lowest resistance was reported to amikacin (AN), gentamicin (GM) and meropenem (MEN) with 0, 1 and 3 resistant samples, respectively. Furthermore, the highest resistance to ampicillin (AM), piperacillin (PIP) and chloramphenicol (CL) were reported with 79, 66 and 67 resistant samples, respectively. By examining the diameter of the inhibition zone, among 80 Klebsiella pneumoniae strains, 51 (63.75٪) were beta-lactamaseproducing isolates and 29 (36.25٪) were carbapenemase-producing isolates.Out of 61 (76٪) samples with multiple resistance, 56 samples formed biofilm.The results of molecular tests for ESBL genes showed only the expression of mcr2 and the amplification of carbapenemase genes was only expressed for mcr2 and fosA3. Discussion and Conclusion: The frequency of Klebsiella pneumoniae isolates that produce biofilm, ESBL and carbapenemase with the expression of mcr-2 and fosA genes are increasing in hospitals.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

mcr-1 Colistin Resistance in ESBL-Producing Klebsiella pneumoniae, France

We report intestinal carriage of an extended-spectrum β-lactamase-producing Klebsiella pneumoniae strain with high-level resistance to colistin (MIC 24 mg/L) in a patient in France who had been hospitalized for fungal meningitis. The strain had the mcr-1 plasmid gene and an inactivated mgrB gene, which are associated with colistin resistance.

full text

Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae.

Sir, Klebsiella pneumoniae is an important pathogen that causes severe and life-threatening infections. Most isolates demonstrate resistance to various antimicrobial agents. Carbapenems have been widely used to treat serious infections with multidrug-resistant K. pneumoniae. However, the increasing use of these compounds has led to the emergence of carbapenem-resistant isolates via acquired gen...

full text

Antibiofilm peptides increase the susceptibility of carbapenemase-producing Klebsiella pneumoniae clinical isolates to β-lactam antibiotics.

Multidrug-resistant carbapenemase-producing Klebsiella pneumoniae (KpC) strains are becoming a common cause of infections in health care centers. Furthermore, Klebsiella can develop multicellular biofilms, which lead to elevated adaptive antibiotic resistance. Here, we describe the antimicrobial and antibiofilm activities of synthetic peptides DJK-5, DJK-6, and 1018 against five KpC isolates. U...

full text

Carbapenemase-producing Klebsiella pneumoniae

The continuing emergence of infections due to multidrug resistant bacteria is a serious public health problem. Klebsiella pneumoniae, which commonly acquires resistance encoded on mobile genetic elements, including ones that encode carbapenemases, is a prime example. K. pneumoniae carrying such genetic material, including both blaKPC and genes encoding metallo-β-lactamases, have spread globally...

full text

Carbapenemase-producing Klebsiella pneumoniae and Hematologic Malignancies

To the Editor: Until a few years ago, the most frequent microbiologi-cally documented cause of severe bloodstream infections among patients with hematologic malignancies was gram-positive bacteria (1). However , over the years, gram-negative bacteria have become the main infectious cause of death among patients with hematologic malignancies, and rates of different phenotypes associated with ant...

full text

Evaluation of antibacterial effects of Zataria multiflora Boiss extracts against ESBL-producing Klebsiella pneumoniae strains

Objective: There are few therapeutic options for treatment of multidrug resistant Klebsiella pneumoniae isolates as a hospital infectious agent (nosocomial infection). The aim of this study was to evaluate the antibacterial activity of Zataria multiflora Boiss extracts against ESBL-producing Klebsiella pneumoniae strains. Materials and Methods: This study was conducted on 100 K. pneumoniae isola...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 17  issue None

pages  1- 11

publication date 2022-12

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

No Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023